Biogen (NASDAQ:BIIB) Insider Priya Singhal Sells 2,660 Shares

Biogen Inc. (NASDAQ:BIIB) insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Priya Singhal also recently made the following trade(s):

• On Monday, February 2nd, Priya Singhal sold 748 shares of Biogen stock. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40.

Biogen Price Performance

Biogen stock traded down $4.82 during mid-day trading on Tuesday, reaching $188.99. 1,836,099 shares of the company’s stock traded hands, compared to its average volume of 1,646,308. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The stock has a 50 day moving average of $177.44 and a two-hundred day moving average of $157.89. The company has a market cap of $27.74 billion, a price-to-earnings ratio of 21.45, a PEG ratio of 1.55 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the previous year, the firm posted $3.44 EPS. The business’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

Hedge Funds Weigh In On Biogen

A number of hedge funds have recently added to or reduced their stakes in the stock. Elevation Point Wealth Partners LLC purchased a new stake in shares of Biogen in the second quarter valued at approximately $25,000. WPG Advisers LLC lifted its holdings in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after buying an additional 117 shares during the period. Rothschild Investment LLC grew its position in shares of Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after buying an additional 88 shares in the last quarter. Accredited Wealth Management LLC grew its position in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares in the last quarter. Finally, Concord Wealth Partners increased its stake in shares of Biogen by 100.0% during the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 114 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on BIIB shares. UBS Group began coverage on Biogen in a report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price target on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Truist Financial raised their target price on shares of Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a report on Monday. Wedbush lifted their price target on shares of Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a research note on Monday. Finally, Tudor Pickering set a $201.00 price objective on shares of Biogen in a research report on Monday. Thirteen equities research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $206.21.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and updated guidance — Biogen reported Q4 results and FY guidance that topped expectations (EPS and revenue beats; FY2026 EPS range of 15.25–16.25), a key driver for recent analyst upgrades and higher targets. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The biologics license application for a subcutaneous formulation of Leqembi (lecanemab) was designated for priority review, which could materially expand the Alzheimer’s franchise if approved. Article Title
• Positive Sentiment: Multiple bullish analyst moves lift upside — Several firms raised price targets and/or maintained Buy ratings after the results and pipeline updates (Goldman Sachs PT raised to $231; RBC to $233; HC Wainwright to $228; Canaccord and others also raised targets), supporting multi-quarter upside expectations. Article Title
• Neutral Sentiment: Pipeline diversification headlines (lupus, SMA) — Management and coverage note advancing programs beyond Alzheimer’s, which improves long-term growth optionality but will take time to materialize. Article Title
• Neutral Sentiment: Mixed analyst stances — Several shops raised price targets but kept neutral/hold ratings (Citigroup, Piper Sandler, Wedbush, Truist), indicating disagreement on valuation even after beats. Article Title
• Neutral Sentiment: Short-interest report appears unreliable — A reported “significant increase” shows zero shares in the feed (data inconsistent); no clear short-covering pressure signaled. (internal short-interest entry)
• Negative Sentiment: Ongoing franchise pressure and execution risk — Coverage notes that legacy multiple sclerosis (MS) franchise pressures and execution on expanding Leqembi access/commercial scale remain risks that could cap near-term upside. Article Title

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.